Jack Stover Net Worth

Jack Stover biography

Jack E. Stover CPA serves as President, Chief Executive Officer, Director of the Company. Mr. Stover has been a member of the Board since 2005 and previously served as Chairman of the Audit Committee of the Board from 2005 to December 22, 2015. He was appointed as our President and Chief Executive Officer effective June 21, 2016. Mr. Stover served as our Interim President and Chief Executive Officer from December 22, 2015 to June 20, 2016. Mr. Stover has been a member of the Board of Directors, Chairman of the Audit Committee, and a member of the Compensation Committee of Onconova Therapeutics, Inc., a publicly held biopharmaceutical company since May 2016. Mr. Stover also was a member of the board of Cernostics, Inc., a privately held molecular diagnostic company, from March 2015 until July 2016. Further, Mr. Stover served as a director and Chairman of the Audit Committee of Viatar CTC Solutions, Inc., a publicly held circulating tumor cell company. From May 2016 until December 2016. Mr. Stover was also previously chief executive officer of Zebec Therapeutics LLC (the successor to Quadrant Pharmaceuticals LLC), a privately held clinical stage specialty pharmaceutical company, from April 2014 until December 2015. From 2009 to February 2012, Mr. Stover served as the executive chairman of Targeted Nano Therapeutics LLC, a privately held biotechnology company focused on targeted delivery of peptides and proteins. Mr. Stover also provided consulting and advisory services through JE Stover Consulting, LLC from 2008 through 2015. Mr. Stover was chairman of the audit committee and a member of the board of directors of Arbios Systems Inc., a publicly held bioartificial liver company from 2005 to 2008 and a member of the board of directors of Influmedix, Inc. a privately held vaccine company from 2010 to 2011.

What is the salary of Jack Stover?

As the President, Chief Executive Officer oraz Director of Interpace Biosciences Inc, the total compensation of Jack Stover at Interpace Biosciences Inc is $862,291. There are no executives at Interpace Biosciences Inc getting paid more.

How old is Jack Stover?

Jack Stover is 67, he's been the President, Chief Executive Officer oraz Director of Interpace Biosciences Inc since 2016. There are 1 older and 7 younger executives at Interpace Biosciences Inc. The oldest executive at Interpace Biosciences Inc is Stephen Sullivan, 73, who is the Chairman of the Board.

What's Jack Stover's mailing address?

Jack's mailing address filed with the SEC is C/O ONCONOVA THERAPEUTICS, INC, 12 PENNS TRAIL, NEWTOWN, PA, 18940.

Insiders trading at Interpace Biosciences Inc

Over the last 9 years, insiders at Interpace Biosciences Inc have traded over $0 worth of Interpace Biosciences Inc stock and bought 94,105 units worth $353,961 . The most active insiders traders include Peter Kamin, Nat Krishnamurti oraz Graham G Miao. On average, Interpace Biosciences Inc executives and independent directors trade stock every 99 days with the average trade being worth of $48,561. The most recent stock trade was executed by Thomas W. Burnell on 21 May 2021, trading 10,855 units of IDXG stock currently worth $94,221.

What does Interpace Biosciences Inc do?

advancing patient care through molecular diagnostic testing. interpace diagnostics develops molecular diagnostic tests. our molecular diagnostic tests provide unparalleled accuracy and clarity to improve outcomes in patients facing a cancer diagnosis. you can be assured that all of the molecular tests we offer are driven by rigorous, validated science. we power the future of molecular diagnostics, delivering cutting-edge and much-needed mutational analysis that helps risk-stratify for thyroid, pancreatic, and other cancers to better inform treatment decisions. the unique molecular diagnostic tests we offer enable healthcare providers to avoid unnecessary surgeries and better assess the risk of cancer progression in their patients.

Interpace Biosciences Inc executives and stock owners

Interpace Biosciences Inc executives and other stock owners filed with the SEC include:

• Jack Stover,
  President, Chief Executive Officer, Director
• Dr. Thomas W. Burnell Ph.D.,
  Pres, CEO & Director
• Fortunato Rocca,
  Independent Director
• Joseph Keegan,
  Independent Director
• Eric Lev,
  Non-Executive Director
• Robert Gorman,
  Director
• Edward Chan,
  Director
• Fred Knechtel,
  Chief Financial Officer, Treasurer, Secretary
• Stephen Sullivan,
  Chairman of the Board
• Patrick Kane,
  VP & Corp. Controller
• Dr. Alidad Mireskandari M.B.A., Ph.D.,
  Chief Devel. Officer
• Dr. Sydney D. Finkelstein,
  Chief Scientific Officer
• Thomas John Freeburg Ph.D.,
  CFO, Treasurer & Sec.
• Nat Krishnamurti,
  Interim CFO
• Graham G Miao,
  CFO
• William Jheartland Advisors...,
  
• Harry Glorikian,
  Director
• 2018 Limited Partnership Am...,
  10% owner
• Thomas W. Burnell,
  President & CEO
• Peter Kamin,
  10% owner
• Laurence Mc Carthy,
  Director
• Felice Schnoll Sussman,
  Director
• Gregory Richard,
  Chief Commerical Officer
• James Early,
  
• Vijay Aggarwal,
  Director
• Christopher Mc Carthy,
  Chief Financial Officer